Clinical Trial: Contribution of F18-FDG PET/CT to the Early Assessment of Pazopanib Therapy Efficacy in Advanced Soft Tissue Sarcoma
Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Observational
Official Title:
Brief Summary:
Soft Tissue Sarcoma (STS) is a rare tumor but can grow in different areas, for example, in 60% in limbs and about 20 % in retroperitoneum; and frequently is inoperable. Despite novel therapy in advanced cases survival is still short, approximately 12 month.
Pazopanib oral angiogenesis inhibitor was recently shown as promising drug for advanced pretreated STS.
Functional imaging especially F18-FDG PET/CT is a good modality for FDG avid tumor either for pre- / post- treatment evaluation or follow up.
Early detection of treatment response to therapy by whole body FDG PET/CT allows for change of treatment as early as possible,when the tumor is non-responsive before serious side effects appear or before depletion of body resources.
The aim of the study is to investigate the contribution of FDG PET/CT to assessment of treatment response.
Detailed Summary:
Sponsor: Hadassah Medical Organization
Current Primary Outcome:
- Measure of extent and intensity (standardized uptake value - SUV) of disease demonstrated on PET/CT images before and after treatment. [ Time Frame: 1 week ]
- determination of treatment efficiency by comparison of PET data (SUV) with CT changes (cm)in 3 studies and clinical information. [ Time Frame: 4 week ]
Original Primary Outcome: Same as current
Current Secondary Outcome: prediction of treatment efficiency [ Time Frame: 6 weeks ]
Original Secondary Outcome: Same as current
Information By: Hadassah Medical Organization
Dates:
Date Received: April 30, 2012
Date Started: May 2012
Date Completion: May 2013
Last Updated: May 7, 2012
Last Verified: April 2012
